Novo Nordisk Falls as FDA Panel to Discuss Insulin Risks

Novo Nordisk A/S, the world’s biggest insulin maker, fell the most in more than 14 months after U.S. regulators disclosed that an advisory panel on the company’s Tresiba diabetes treatment will focus on heart risks.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.